PNC Financial Services Group Inc. Buys Shares of 1,798 Inhibrx, Inc. (NASDAQ:INBX)

PNC Financial Services Group Inc. purchased a new position in Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 1,798 shares of the company’s stock, valued at approximately $28,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in INBX. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Inhibrx during the 4th quarter valued at $348,000. Exchange Traded Concepts LLC bought a new position in Inhibrx during the fourth quarter valued at about $148,000. Bank of New York Mellon Corp bought a new position in Inhibrx during the fourth quarter valued at about $792,000. China Universal Asset Management Co. Ltd. acquired a new position in Inhibrx during the fourth quarter worth about $47,000. Finally, Rhumbline Advisers bought a new stake in Inhibrx in the fourth quarter worth about $228,000. Institutional investors own 82.46% of the company’s stock.

Analyst Ratings Changes

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Price Performance

Shares of NASDAQ:INBX opened at $14.32 on Friday. The company’s fifty day moving average is $13.35 and its two-hundred day moving average is $14.61. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $35.42.

Inhibrx (NASDAQ:INBX) last released its earnings results on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. On average, equities research analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.